Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Ruane

Showing results (11-20 of 39) with videos related to

Pageof 4
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|August 29, 2006
Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patientsEdwin DeJesus, Daniel Berger, Martin Markowitz, et al.
Antiviral Therapy|June 9, 2006
The safety and tolerability of Z-100 in patients infected with HIV-1Michael Borucki, Mark Holodniy, Gerald Pierone, et al.
Biology of Reproduction|November 14, 2025
Bovine endometrial organoids: A new tool to study conceptus-maternal interactions in mammalsJessica C Edge, Olga Amelkina, Haidee Tinning, et al.
Journal of Viral Hepatitis|January 22, 2019
Sofosbuvir/Velpatasvir/Voxilaprevir for patients with HCV who previously received a Sofosbuvir/Velpatasvir-containing regimen: Results from a retreatment studyPeter Ruane, Simone I Strasser, Edward J Gane, et al.
AIDS (London, England)|March 18, 2011
Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infectionCalvin Cohen, Richard Elion, Peter Ruane, et al.
The Journal of Infectious Diseases|March 23, 2017
TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on DarunavirDavid Wyles, Michael Saag, Rolando M Viani, et al.
HIV Clinical Trials|December 13, 2006
Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infectionPeter Ruane, Joseph Lang, Edwin DeJesus, et al.
AIDS (London, England)|March 28, 2014
Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participantsFrank J Palella, Martin Fisher, Pablo Tebas, et al.
The Lancet. HIV|June 22, 2018
Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trialJean-Michel Molina, Douglas Ward, Indira Brar, et al.
Open Forum Infectious Diseases|July 17, 2024
Dolutegravir/Lamivudine Efficacy and Safety Outcomes in People With HIV-1 With or Without Historical Resistance Results at Screening: 48-Week Pooled AnalysisStefan Scholten, Pedro Cahn, Joaquín Portilla, et al.
Pageof 4

Showing results (11-20 of 39) with videos related to

Sort By:
Pageof 4
Journal of Acquired Immune Deficiency Syndromes (1999)|August 29, 2006
Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patientsEdwin DeJesus, Daniel Berger, Martin Markowitz, et al.
Antiviral Therapy|June 9, 2006
The safety and tolerability of Z-100 in patients infected with HIV-1Michael Borucki, Mark Holodniy, Gerald Pierone, et al.
Biology of Reproduction|November 14, 2025
Bovine endometrial organoids: A new tool to study conceptus-maternal interactions in mammalsJessica C Edge, Olga Amelkina, Haidee Tinning, et al.
Journal of Viral Hepatitis|January 22, 2019
Sofosbuvir/Velpatasvir/Voxilaprevir for patients with HCV who previously received a Sofosbuvir/Velpatasvir-containing regimen: Results from a retreatment studyPeter Ruane, Simone I Strasser, Edward J Gane, et al.
AIDS (London, England)|March 18, 2011
Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infectionCalvin Cohen, Richard Elion, Peter Ruane, et al.
The Journal of Infectious Diseases|March 23, 2017
TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on DarunavirDavid Wyles, Michael Saag, Rolando M Viani, et al.
HIV Clinical Trials|December 13, 2006
Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infectionPeter Ruane, Joseph Lang, Edwin DeJesus, et al.
AIDS (London, England)|March 28, 2014
Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participantsFrank J Palella, Martin Fisher, Pablo Tebas, et al.
The Lancet. HIV|June 22, 2018
Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trialJean-Michel Molina, Douglas Ward, Indira Brar, et al.
Open Forum Infectious Diseases|July 17, 2024
Dolutegravir/Lamivudine Efficacy and Safety Outcomes in People With HIV-1 With or Without Historical Resistance Results at Screening: 48-Week Pooled AnalysisStefan Scholten, Pedro Cahn, Joaquín Portilla, et al.
Pageof 4